2005
DOI: 10.1176/appi.ajp.162.4.815
|View full text |Cite
|
Sign up to set email alerts
|

5-Methoxy-N,N-Diisopropyltryptamine-Induced Flashbacks

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
27
1
1

Year Published

2006
2006
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 69 publications
(31 citation statements)
references
References 4 publications
2
27
1
1
Order By: Relevance
“…5-MEO-DIPT was first synthesized by Shulgin and Carter (1980) and was described as inducing auditory and visual hallucinations in humans lasting 3-6 h. Emergency room reports and recent case studies confirm the auditory and visual hallucinogenic properties of 5-MEO-DIPT and suggest that the drug can also produce tactile hallucinations, agitation, tachycardia, somatic disturbance, cataleptic states, unconsciousness, flashbacks, increased glucose levels, vomiting, rhabdomyolysis, and in at least one case, seizure activity or death (Alatrash et al, 2006;Ikeda et al, 2005;Kiyota, 2004;Meatherall and Sharma, 2003;Muller, 2004;Smolinske et al, 2004;Tanaka et al, 2006;Wilson et al, 2005). From case studies, users have reported administering various amounts of the drug (ie, 10-37.5 mg) via oral or rectal routes of administration (Ikeda et al, 2005;Kiyota, 2004).…”
Section: Introductionmentioning
confidence: 94%
See 2 more Smart Citations
“…5-MEO-DIPT was first synthesized by Shulgin and Carter (1980) and was described as inducing auditory and visual hallucinations in humans lasting 3-6 h. Emergency room reports and recent case studies confirm the auditory and visual hallucinogenic properties of 5-MEO-DIPT and suggest that the drug can also produce tactile hallucinations, agitation, tachycardia, somatic disturbance, cataleptic states, unconsciousness, flashbacks, increased glucose levels, vomiting, rhabdomyolysis, and in at least one case, seizure activity or death (Alatrash et al, 2006;Ikeda et al, 2005;Kiyota, 2004;Meatherall and Sharma, 2003;Muller, 2004;Smolinske et al, 2004;Tanaka et al, 2006;Wilson et al, 2005). From case studies, users have reported administering various amounts of the drug (ie, 10-37.5 mg) via oral or rectal routes of administration (Ikeda et al, 2005;Kiyota, 2004).…”
Section: Introductionmentioning
confidence: 94%
“…In Shulgin and Carter's initial human study, users reported effects (ie, hallucinations, etc.) when 5-MEO-DIPT was taken at a dose of 6-10 mg; however from the various case studies and other sources (eg, www.Erowid.com), it is reported that the drug is taken at higher concentrations (up to 100 mg per 'hit') and may be taken multiple times on a single day (Ikeda et al, 2005;Kiyota, 2004).…”
Section: Effects Of 5-meo-diptmentioning
confidence: 99%
See 1 more Smart Citation
“…Three clinical case reports [2][3][4] and one experimental study [5] have concerned 5-MeO-DIPT intoxication. Meatherall & Sharma [3] reported that 5-MeO-DIPT may cause mild hallucinations and motor disturbances lasting for 3.5 hours, while Wilson et al [4] reported transient tactile hallucinations resolving after 4 hours of observation in an emergency ward.…”
Section: Discussionmentioning
confidence: 99%
“…Taken together, these reports appeared to suggest that psychotic symptoms induced by 5-MeO-DIPT may be relatively transient, or lasting several hours at the most. However, Ikeda et al [2] have described auditory hypersensitivity and persistent visual distortions. No reports, however, mentioned severely disordered conduct or disturbances of consciousness induced by 5-MeO-DIPT.…”
Section: Discussionmentioning
confidence: 99%